Melanoma Registry of the Spanish Academy of Dermatology and Venereology (REGESMEL): Description and Data in its First Year of Operation. / Registro de Melanoma de la Academia Española de Dermatología y Venereología (REGESMEL): descripción y datos en el primer año de funcionamiento.

INTRODUCTION: The incidence of melanoma is rising in Spain. The prognostic stages of patients with melanoma are determined by various biological factors, such as tumor thickness, ulceration, or the presence of regional or distant metastases. The Spanish Academy of Dermatology and Venereology (AEDV) has encouraged the creation of a Spanish Melanoma Registry (REGESMEL) to evaluate other individual and health system-related factors that may impact the prognosis of patients with melanoma. The aim of this article is to introduce REGESMEL and provide basic descriptive data for its first year of operation. METHODS: REGESMEL is a prospective, multicentre cohort of consecutive patients with invasive cutaneous melanoma that collects demographic and staging data as well as individual and healthcare-related baseline data. It also records the medical and surgical treatment received by patients. RESULTS: A total of 450 cases of invasive cutaneous melanoma from 19 participant centres were included, with a predominance of thin melanomas≤1mm thick (54.7%), mainly located on the posterior trunk (35.2%). Selective sentinel lymph node biopsy was performed in 40.7% of cases. Most cases of melanoma were suspected by the patient (30.4%), or his/her dermatologist (29.6%). Patients received care mainly in public health centers (85.2%), with tele-dermatology resources being used in 21.6% of the cases. CONCLUSIONS: The distribution of the pathological and demographic variables of melanoma cases is consistent with data from former studies. REGESMEL has already recruited patients from 15 Spanish provinces and given its potential representativeness, it renders the Registry as an important tool to address a wide range of research questions.

Elastosis perforante serpiginosa / Elastosis perforans serpinginosa

La Elastosis perforante serpiginosa es una rara dermatosis crónica caracterizada por eliminación de fibras elásticas alteradas, a través de la epidermis. A menudo aparece asociada con distintos trastornos del tejido conectivo y puede desarrollarse después de un tratamiento con penicilamina. Sin embargo, también pueden presentarse de forma idiopática. No se conoce el mecanismo por el que se modifican las fibras elásticas y, lamentablemente, no hay ningún tratamiento para esta enfermedad que haya demostrado evidencia. Describimos un caso de elastosis idiopática perforante serpiginosa en placa, tratada de forma satisfactoria con láser de CO2 (AU)

Elastosis perforans serpiginosa is a rare chronic dermatosis characterized by extrusion of altered elastic fibers through the epidermis. It often occurs in association with a variety of connective tissue disorders, and may develop following penicillamine therapy; however, it may also present without c morbidities. The mechanism by which the elastic fibers are altered is not known and, unfortunately, there are no evidence-based treatments for this disease. We describe one patient with idiopathic elastosis perforans serpiginosa in patch pattern, which was successfully treated with CO2laser (AU)

Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis.

OBJECTIVES: The aim of this study was to test the efficacy of latanoprost in eyelash alopecia areata (AA). DESIGN: This study is a 2-year prospective, non-blinded, non-randomized, bilateral eyelash alopecia controlled study. SETTING: The setting of this study was Trichology Unit, Virgen Macarena University Hospital, Seville, Spain. PATIENTS: We conducted a survey of 54 subjects with AA universalis treated with the protocol of the Trichology Unit of our Department. Control group comprised 10 subjects who received injections of 0.5 mg/cm(2) of triamcinolone acetonide (TAC) in their eyebrows and 1 mg/cm(2) of TAC injections in affected scalp. The treatment group included 44 subjects who received the same treatment as the control group in scalp and eyebrows but they also applied a drop of latanoprost 0.005% (50 microg/mL) ophthalmic solution in their eyelid margins every night. Subjects were reviewed every 3 months for 2 years. RESULTS: Forty subjects finished the study and four subjects were lost to follow-up. In the treatment arm of this study, the course was well tolerated and uncomplicated. Both investigators and patients evaluated the regrowth. The results we obtained were: complete regrowth in 17.5%, moderate regrowth in 27.5%, slight regrowth in 30% and without response in 25%. Moderate and total regrowth constituted a cosmetically acceptable response. The therapy was continuous and the response remained without any side effects. No patients had cosmetically acceptable eyelash regrowth in the control group. CONCLUSIONS: Latanoprost may be an effective drug in the treatment of eyelash AA because it induces acceptable responses (total and moderate) in 45% of the patients. A formal, blinded prospective unilateral controlled study will permit further understanding about this promising therapeutic agent for eyelash AA.

El lupus eritematoso en la consultade dermatología / Lupus erythematosus in dermatological practice

El lupus eritematoso (LE) es una enfermedad que presenta manifestaciones cutáneas en más del 80% de los pacientes. El propósito de este estudio esconocer la incidencia de las manifestaciones cutáneas de esta enfermedad en la mucosa oral y cuero cabelludo que, a menudo, pasan desapercibidaspara el clínico e incluso para el paciente. Además, se valoró la eficacia del tratamiento con inmunomoduladores tópicos en todos los tipos clínicos. Paraello, revisamos 63 pacientes diagnosticados de LE que asistieron a una consulta de Dermatología del Hospital Universitario Virgen Macarena entre septiembrey diciembre del 2005, incluyendo las formas sistémica, subaguda y discoide.Se analizaron datos demográficos, formas clínicas, localización de las lesiones, exposición solar, pruebas analíticas, histopatología y tratamiento.Observamos una alta frecuencia de lesiones en mucosa oral y cuero cabelludo y obtuvimos buenos resultados terapéuticos con el uso de inmunomoduladorestópicos en todos los tipos clínicos (AU)

Lupus erythematosus (LE) is a sistemic disease with cutaneous manifestations in more than 80% of the patients. The aim of the study is to know theincidence of manifestations at oral mucosa and scalp, which are frequently unnoticed to the physician and the patient. Moreover, we evaluated theefficacy of topical immunomodulators in all the types of LE. Sixty three patients diagnosed of LE who came to a consultation at the Department of Dermatologyat the Virgen Macarena Universitary Hospital from september to december of 2005 were reviewed. We included the systemic, subacute anddiscoid forms of LE. Demographic data, clinical types, location of the lesions, photoexposition, serology, histopathology and treatment followed bythe patients were considerated.We observed a high proportion of lesions at the oral mucosa and scalp. Finally, we obtained good therapeutical results using topical immunomodulatorsin all clinical types of lupus (AU)

Síndrome de las uñas amarillas / Yellow nail síndrome

No disponible

No disponible

Angiosarcoma de cuero cabelludo secundario a radioterapia / Radiotherapy-induced scalp angiosarcoma

No disponible

No disponible

[Narrow band UVB therapy in early stage mycosis fungoides. A study of 23 patients]. / Tratamiento con UVB de banda estrecha de los estadios iniciales de la micosis fungoide. Estudio de 23 pacientes.

INTRODUCTION: Phototherapy is effective for mycosis fungoides. Narrow band UVB (UVB1) therapy is being used as an alternative to PUVA therapy for its efficacy and less adverse events. The objective of the study was to determine the efficacy of narrow band UVB therapy in early stage mycosis fungoides. METHODS: It is a retrospective study of 23 patients with stage IB mycosis fungoides that have received UVB1 therapy following the phototherapy protocol of the Spanish Photobiology Group. RESULTS: Thirteen patients (57 %) had a complete response, eight patients (35 %) had a partial response and two patients (8 %) did not respond. Half of the patients with complete response (n = 6) relapsed after one year of follow-up. CONCLUSIONS: We consider that UVB1 therapy is a good alternative for treatment of early stage mycosis fungoides, although the disease-free period is short.

Tratamiento con UVB de banda estrecha de los estadios iniciales de la micosis fungoide. Estudio de 23 pacientes / Narrow band UVB therapy in early stage mycosis fungoides. A study of 23 patients

Introducción. La fototerapia ha demostrado ser de utilidad en la micosis fungoide. La radiación UVB de banda estrecha (UVB1) está siendo utilizada como alternativa a la radiación UVA por su eficacia y menores efectos secundarios. El objetivo del estudio fue determinar la eficacia del tratamiento de la fototerapia con UVB1 en los estadios iniciales de la micosis fungoide. Métodos. Estudio retrospectivo sobre 23 pacientes con micosis fungoide en estadio IB que habían recibido fototerapia con UVB, según el protocolo de fototerapia del Grupo Español de Fotobiología. Resultados. Se obtuvo respuesta completa en 13 pacientes (57 %), respuesta parcial en 8 (35 %) y no respondieron 2 (8 %). La mitad de los pacientes con respuesta completa que finalizaron el año de seguimiento (n = 6) presentaron recidivas. Conclusiones. Consideramos que la fototerapia con UVB1 es una buena opción en el tratamiento de las fases iniciales de la micosis fungoide, aunque el intervalo libre de enfermedad no es prolongado

Introduction. Phototherapy is effective for mycosis fungoides. Narrow band UVB (UVB1) therapy is being used as an alternative to PUVA therapy for its efficacy and less adverse events. The objective of the study was to determine the efficacy of narrow band UVB therapy in early stage mycosis fungoides. Methods. It is a retrospective study of 23 patients with stage IB mycosis fungoides that have received UVB1 therapy following the phototherapy protocol of the Spanish Photobiology Group. Results. Thirteen patients (57 %) had a complete response, eight patients (35 %) had a partial response and two patients (8 %) did not respond. Half of the patients with complete response (n = 6) relapsed after one year of follow-up. Conclusions. We consider that UVB1 therapy is a good alternative for treatment of early stage mycosis fungoides, although the disease-free period is short